Hepion Pharmaceuticals Announces Participation in the H.C. Wainwright BioConnect Conference
January 05 2022 - 4:30PM
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage
biopharmaceutical company focused on Artificial Intelligence
(“AI”)-driven therapeutic drug development for the treatment of
non-alcoholic steatohepatitis (“NASH”) and other liver diseases,
today announced that it will participate in the H.C. Wainwright
BioConnect Conference, to be held virtually January 10-13, 2022.
Hepion’s pre-recorded presentation will be
available on demand during the event for all registered attendees.
Beginning on Monday, January 10, 2022, the presentation will also
be available on the Company's website at www.hepionpharma.com under
“Events” in the “Investors” section.
About Hepion
Pharmaceuticals
The Company's lead drug candidate, CRV431, is a
potent inhibitor of cyclophilins, which are involved in many
disease processes. CRV431 is currently in clinical-phase
development for the treatment of NASH, with the potential to play
an important role in the overall treatment of liver disease - from
triggering events through to end-stage disease. CRV431 has been
shown to reduce liver fibrosis and hepatocellular carcinoma tumor
burden in experimental models of NASH; and has demonstrated
antiviral activities towards HBV, HCV, and HDV through several
mechanisms, in nonclinical studies.
Hepion has created a proprietary AI platform,
called AI-POWR™, which stands for Artificial
Intelligence - Precision Medicine;
Omics (including genomics, proteomics,
metabolomics, transcriptomics, and lipidomics);
World database access; and
Response and clinical outcomes. Hepion intends to
use AI-POWR™ to help identify which NASH patients will best respond
to CRV431, potentially shortening development timelines and
increasing the delta between placebo and treatment groups. In
addition to using AI-POWR™ to drive its ongoing NASH clinical
development program, Hepion intends to use the platform to identify
additional potential indications for CRV431 to expand the company's
footprint in the cyclophilin inhibition therapeutic space.
For further information, please contact:
Stephen KilmerHepion Pharmaceuticals Investor
RelationsDirect: (646) 274-3580skilmer@hepionpharma.com
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Sep 2023 to Sep 2024